Menu
Recruiting NCT05090267

The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study

No phase Interventional Cognition Gut Microbiome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Probiotic Supplement, Transcutaneous Vagal Nerve Stimulation (tVNS).
Who it may be relevant to
Registry conditions: Cognition, Gut Microbiome. Basic parameters: 35 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study

Overview

This project uses a hybrid trial design to evaluate two biomedical interventions targeting the gut-brain axis. One intervention is portable Transcutaneous Vagus Nerve Stimulator, tVNS, that is hypothesized to stimulate the autonomic nervous system, resulting in decreased inflammation and improved cognition. The second intervention is a probiotic supplement intended to replace gut bacteria that are associated with dysbiosis in persons with HIV and alcohol consumption.

Interventions

  • Dietary supplement Probiotic Supplement
    Participants will take a probiotic supplement or placebo for 90 days.
  • Device Transcutaneous Vagal Nerve Stimulation (tVNS)
    Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.

Primary outcome measures

  • Improved cognition from day 1 to day 90 [Time frame: Baseline up to 90 days]
  • Reduction of dysbiosis from day 1 to day 90 [Time frame: Baseline up to 90 days]

Eligibility criteria

Inclusion criteria

  • Age 35-70 years
  • English or Spanish speaking
  • Alcohol users
  • Cognitive impairment
  • Current CD4>350

Exclusion criteria

  • Diagnosed major psychiatric illness
  • Consumption of over 300 drinks in the past 30 days
  • Recent opioid use
  • Lifetime history of medically-assisted alcohol detoxification
  • Inpatient or intensive treatment for addictive behaviors in the past 12 months
  • MRI contraindications
  • Current antibiotic treatment
  • Current probiotic use
  • Physical impairment precluding motor response or lying still.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Factorial
Masking
Double blind
Primary purpose
Basic science

Study locations

United States · 1 center
  • University of Miami — Coral Gables

Identifiers

NCT: NCT05090267 · CED000000532 · P01AA029543 · PRO00035889

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗